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Graft versus host disease (GVHD) is the major complication of allogeneic hematopoietic
stem cell transplantation. GVHD is characterized by an imbalance between the effector
and regulatory arms of the immune system which results in the over production of inflam-
matory cytokines. Moreover, there is a persistent reduction in the number of regulatory T
(Treg) cells which limits the ability of the immune system to re-calibrate this proinflamma-
tory environment. Treg cells are comprised of both natural and induced populations which
have unique ontological and developmental characteristics that impact how they function
within the context of immune regulation. In this review, we summarize pre-clinical data
derived from experimental murine models that have examined the role of both natural and
induced Treg cells in the biology of GVHD. We also review the clinical studies which have
begun to employ Treg cells as a form of adoptive cellular therapy for the prevention of
GVHD in human transplant recipients.
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GRAFT VERSUS HOST DISEASE
Although hematopoietic stem cell transplantation (HSCT) has
been a successful therapeutic strategy for treating hematological
malignancies for several decades, its broad application is lim-
ited by the high incidence of graft versus host disease (GVHD).
GVHD is primarily a donor T cell-mediated syndrome whereby
T cells in the graft elicit an immune response, resulting in host
tissue damage (Korngold and Sprent, 1978). HSCT recipients typ-
ically receive conditioning regimens consisting of chemotherapy
and/or radiation in order to eliminate their underlying malig-
nancy and facilitate the engraftment of allogeneic stem cells.
However, the conditioning regimen can cause damage to host
tissues, triggering the release of proinflammatory cytokines such
as TNF-α, interleukin-1β, and interleukin-6, and activating the
innate immune system, including host antigen presenting cells
(APCs) (Hill et al., 1997; Shlomchik et al., 1999). Early following
transplantation, donor T cells in the graft interact with activated
host APCs, recognize presented host peptides as foreign, and dif-
ferentiate into cytokine-producing T effector cells. The ensuing
proinflammatory cytokine storm recruits other effector cells, like
NK cells and macrophages. This perpetuates the proinflammatory
cytokine cascade that is a hallmark of acute GVHD (aGVHD)
and results in direct tissue damage, generally to a restricted set
of organs (i.e., skin, liver, and gastrointestinal tract) (Antin and
Ferrara, 1992). A second phase of GVHD, known as chronic
GVHD (cGVHD) tends to have a more delayed presentation in
patients, broader organ involvement, and clinical features that
bear strong resemblance to autoimmune disorders (Graze and
Gale, 1979). Both aGVHD and cGVHD can be characterized as
resulting from an imbalance between the effector and regula-
tory arms of the immune system (Chen et al., 2009). Clinical
approaches that restore effective immune regulation are therefore
an attractive treatment strategy for GVHD, which currently has
no FDA-approved therapies. To that end, regulatory T (Treg) cells
which are potent suppressors of immune responses have been a
focal point of research studies designed to mitigate the severity of
GVHD in both pre-clinical murine models and in early stage clini-
cal trials. The optimization of these approaches, however, requires
a thorough understanding of the various Treg cell subsets and
how they coordinately regulate alloreactive donor T cell responses
during GVHD.
CD4+ TREG CELL SUBSETS
In 1995, Sakaguchi et al. (1995) identified a suppressive popula-
tion of CD4+ T cells that expressed high levels of the IL-2 receptor
α-chain (CD25). These cells, termed Treg cells, express the fork-
head box transcription factor Foxp3, which is both necessary and
sufficient for the suppressive ability of Treg cells (Fontenot et al.,
2005). Importantly, there are two distinct subsets of CD4+ Treg
cells. Natural Treg (nTreg) cells comprise 5–10% of the CD4+ T cell
compartment and develop in the thymus (Sakaguchi et al., 2006).
During negative selection, nTreg cells upregulate Foxp3 when they
recognize self-antigen rather than undergoing clonal deletion.
nTreg cells are responsible for maintaining immune homeosta-
sis and tolerance to self-antigen by inhibiting self-reactive T cells
in the periphery (Sakaguchi et al., 2006; Curotto de Lafaille and
Lafaille, 2009). A second subset of Treg cells which has been termed
induced Treg (iTregs) cells is generated when conventional T cells
are activated in the context of TGF-β and IL-2, resulting in the
upregulation of Foxp3 (Fantini et al., 2004). Alternatively, iTregs
can also be induced in a TGF-β-independent fashion (Schallen-
berg et al., 2010). Although the role of iTreg cells in controlling
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the immune response is not completely understood, these cells
are thought to be important for regulating peripheral T cell acti-
vation during infection and mediating the contraction phase of
the immune response (Curotto de Lafaille and Lafaille, 2009).
iTreg cells can also be generated in vitro by activating naive T
cells with either antigen or anti-CD3/anti-CD28 antibodies in the
presence of TGF-β and IL-2 (Chen et al., 2003; Fantini et al., 2004).
In vitro-generated iTreg cells are clinically attractive since they can
be grown in large numbers which facilitates the adoptive transfer of
these cells into recipients under conditions where obtaining a sim-
ilar number of nTreg cells may be logistically difficult. The relative
roles of nTreg and iTreg cells in regulating immune responses and
the extent to which they have unique or overlapping capabilities,
however, has not been defined and is an area of active investi-
gation. Studies performed by Haribhai et al. in murine models
of colitis or Foxp3-deficiency both suggest that nTreg cells and
in vivo-derived iTreg cells have distinct roles in preventing dis-
ease and that these populations act in a complementary fashion
to reduce inflammation (Haribhai et al., 2009, 2011). Elucidating
whether a similar relationship exists between these two Treg cell
populations in GVHD has not been critically examined.
ROLE OF CD4+ nTREG CELLS IN PRE-CLINICAL MODELS OF
GVHD
Since GVHD is characterized by the loss of tolerance and the
development of autoimmune manifestations, it is reasonable to
postulate that a deficiency in Treg cell reconstitution plays a crit-
ical role in GVHD pathophysiology. In fact, studies in mice have
demonstrated that there is a progressive loss of Treg cells during
aGVHD, and this leads to the emergence of autoreactive proin-
flammatory donor T cells (Chen et al., 2007). These cells are able
to mediate pathological damage when re-exposed to self antigens
which leads to autoimmunity, a hallmark of cGVHD. Thus, the
absence of Treg cells appears to contribute to both aGVHD and
cGVHD.
Given the critical role of Treg cells in the maintenance of
tolerance, several groups have tested the hypothesis that the adop-
tive transfer of Treg cells should ameliorate disease by restoring
defective tolerance mechanisms. These studies have been typically
performed by the isolation of CD4+ CD25+ T cells from the spleen
and secondary lymphoid tissue, or more recently, by obtaining
Treg cells from reporter mice in which GFP and Foxp3 proteins
are co-expressed in transgenic animals. It should be noted that
this population of cells which is generally considered to consist of
nTreg cells may actually include some iTreg cells, as there are cur-
rently no reliable markers to distinguish the two subsets (Curotto
de Lafaille and Lafaille, 2009). However, since iTreg cells must be
activated in order to upregulate Foxp3 (Fantini et al., 2004), naïve
mice are presumed to have much lower numbers of iTreg cells.
Therefore, CD4+ Foxp3+ T cells isolated from naïve mice have
been operationally considered to be nTreg cells.
The first published study was from Taylor et al. (2002) who
reported that both depletion of CD25+ T cells from the trans-
plant inoculum as well as in vivo CD25+ T cell depletion after
transplantation was associated with worsening of GVHD. In con-
trast, the adoptive transfer of CD4+ CD25+ nTreg cells along
with the marrow graft resulted in the amelioration of disease.
Since nTreg cells are difficult to isolate in large numbers from the
spleen and secondary lymphoid tissues, this group ex vivo acti-
vated and expanded CD4+ CD25+ T cells, and demonstrated that
these expanded nTreg cells were also potent suppressors of GVHD
(Taylor et al., 2002). These results were rapidly confirmed by other
investigators (Hoffmann et al., 2002; Edinger et al., 2003). Sub-
sequent studies demonstrated that adoptively transferred nTreg
cells must be of donor origin and that their suppressive ability
was due, at least in part, to IL-10 secretion (Hoffmann et al.,
2002; Tawara et al., 2012). Notably, nTreg cell adoptive transfer
was most effective when these cells were transferred before or at
the time of transplantation, while cell transfer at later time points
post transplantation was less effective at attenuating disease sever-
ity (Hoffmann et al., 2002; Taylor et al., 2002; Edinger et al., 2003).
The critical role for timing derived from the fact that nTreg cells are
necessary for inhibiting the early expansion of alloreactive donor
T cells (Edinger et al., 2003).
Early post transplantation, nTreg cells migrate to secondary
lymphoid organs, where they interact with effector T cells (Nguyen
et al., 2007) (Figure 1). Two studies concluded that only CD62Lhi
nTreg cells and not CD62Llo nTreg cells were able to mitigate
GVHD, suggesting that migration to the spleen and lymph nodes
early post transplantation is critical for nTreg cell suppressive func-
tion (Taylor et al., 2004; Ermann et al., 2005). This was further
evidenced by the fact that CD62Llo nTregs were able to suppress
alloreactive T cell proliferation in vitro but were non-functional
in vivo (Ermann et al., 2005). Subsequent studies demonstrated
that nTreg cells were necessary during T cell priming in order to
suppress GVHD-induced CD8+ T cell proliferation (Wang et al.,
2009) and render CD8+ T cells anergic (Kim et al., 2006). A
requirement for host antigen presentation on host APCs was also
identified to be both necessary and sufficient for nTreg cells to
attenuate lethal GVHD (Tawara et al., 2010).
Studies involving chemokine receptor expression on nTreg cells
further elucidated the importance of trafficking in nTreg cell-
mediated suppression of GVHD. CXCR3, CCR5, and CCR6 are
chemokine receptors that are responsible for directing cells toward
GVHD target organs (liver, lung, intestine) which are the sites
of GVHD-associated tissue damage (Wysocki et al., 2005; Varona
et al., 2006; Hasegawa et al., 2008). nTreg cells transfected with
CXCR3 display increased protection against GVHD as compared
to untransfected nTreg cells (Hasegawa et al., 2008). Similarly,
nTreg cells that are either CCR5 or CCR6 deficient exhibit dimin-
ished suppressive function in vivo despite their potent suppressive
function in vitro, as they are unable to migrate to sites of inflam-
mation (Wysocki et al., 2005; Varona et al., 2006). Zhao et al.
(2008) also reported that CD4+ CD103+ Foxp3+ nTreg cells
migrate directly to GVHD target organs due to high expression
of CCR5 and low expression of CD62L, and are able to ameliorate
cGVHD severity, providing additional confirmation that Treg cell
trafficking is critical for optimal protection from GVHD.
Although ex vivo nTreg cell adoptive transfer studies have been
relatively successful in preventing lethal GVHD, in vivo expansion
of nTreg cells may provide a more clinically relevant approach
for nTreg cell therapy. As previously noted, nTreg cells repre-
sent a minor population in the periphery; thus isolating these
cells in sufficient numbers for clinical use may be challenging.
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FIGURE 1 | Proposed mechanism(s) ofTreg cell suppression during
GVHD. (A). nTreg cells migrate to secondary lymphoid tissues, where they
prevent allorecognition by blocking the interaction between T cells and
dendritic cells. (B,C) nTreg and iTreg cells inhibit T cell activation in the
periphery by various mechanisms including cytokine deprivation, inhibitory
receptors, and release of suppressive cytokines. (D) A subset of nTreg and
iTreg cells lose Foxp3 expression and begin to secrete proinflammatory
cytokines due to unknown environmental cues. The role of these cells in
mediating pathological damage during GVHD is unknown. (This figure was
created using Visi ScienceSlides® Software).
Furthermore, while ex vivo expansion of nTreg cells preserves their
suppressive function, conducting clinical protocols that require
extended cell culture can be expensive, technically challenging,
and difficult to implement in many centers. In vivo expansion
of nTreg cells is therefore an attractive option when confronted
with limited resources for clinical translation. To that end, several
pre-clinical studies have demonstrated feasibility of this approach.
One strategy has employed IL-6 receptor blockade to increase
both nTreg and iTreg cell numbers in animals undergoing GVHD.
Mice treated with an anti-IL-6R monoclonal antibody exhib-
ited increased Treg cell reconstitution, decreased proinflammatory
cytokine secretion, and improved overall survival (Chen et al.,
2009). These studies are particularly relevant given that there
is currently an FDA-approved anti-IL-6R antibody, Tocilizumab,
which has shown activity in steroid refractory GVHD (Drobyski
et al., 2011), although whether this is attributable to an increase
in Treg cell numbers awaits further study. An alternative approach
has employed a monoclonal anti-CD28 antibody that acts as a
superagonist and results in the preferential expansion of nTreg
cells and a corresponding mitigation in GVHD severity (Kitazawa
et al., 2009).
Pharmacological strategies have also been tested in murine
GVHD models to determine whether Treg cell numbers can be
augmented after allogeneic HSCT. To that end, Shin et al. (2011)
demonstrated that the in vivo administration of rapamycin plus
IL-2 antibody complexes expanded the nTreg cell population and
reduced GVHD severity. Furthermore, a synthetic derivative of
a-galactosylceramide (KRN7000) which is a ligand for the CD1d
molecule has been shown to expand donor-derived Treg cells in a
dose-dependent manner and reduce GVHD-associated mortality
(Duramad et al., 2011). It is pertinent to note that it is difficult to
distinguish between in vivo expansion of nTreg cells and in vivo
conversion and/or expansion of iTreg cells. Thus, it is difficult to
exclude that these approaches may also result in the expansion of
iTreg cell populations as well.
ROLE OF CD4+ iTREG CELLS IN PRE-CLINICAL MODELS OF
GVHD
While the majority of rodent models of GVHD have focused on the
biology of nTreg cells, there has been much less attention devoted
to the role of iTreg cells in GVHD biology. This has been due, in
part, to the fact that there are no proven cell surface markers that
distinguish nTreg cells from iTreg cells. Consequently, isolation of
a pure iTreg cell population from donor animals for selective adop-
tive transfer studies is not currently feasible. Furthermore, de novo
iTreg cell generation in recipient mice is negligible during GVHD
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(Chen et al., 2009; Beres et al., 2011), making identification and
isolation of these cells in the host problematic as well. However,
iTreg cells can be easily generated from the conventional T cell pool
and expanded in culture (Fantini et al., 2004; Beres et al., 2011).
For this reason, the study of iTreg cells during GVHD has been
almost exclusively limited to the in vitro induction/expansion of
this population followed by adoptive transfer into recipient ani-
mals. In initial studies, iTreg cells were stimulated with allogeneic
dendritic cells or treatment with anti-CD3/anti-CD28 antibod-
ies in the presence of TGF-β and IL-2 to induce Foxp3 expression.
Administration of in vitro-differentiated iTreg cells along with BM
grafts containing alloreactive donor T cells did not result in any
significant protection from lethal aGVHD (Koenecke et al., 2009;
Beres et al., 2011), although one study did demonstrate efficacy in
a lupus-like cGVHD model (Zheng et al., 2004). A major reason
for the lack of observed protection in the aGVHD models was the
fact that there was limited in vivo survival of these cells which was
accompanied by instability of Foxp3 expression, resulting in a loss
of suppressive function early post transplantation (Koenecke et al.,
2009; Beres et al., 2011).
The reason that iTreg cells are unstable in vivo is not clear, but
one potential explanation is that the proinflammatory cytokine
milieu that occurs during GVHD may also render iTreg cells
more unstable. Supporting this premise are data demonstrating
that in vivo-derived iTreg cell conversion is significantly enhanced
when mice are treated with monoclonal antibodies that block
signaling through IL-6 or IL-21 which serves to reduce inflam-
matory cytokine production (Bucher et al., 2009; Chen et al.,
2009). Notably, both of these cytokines signal through Stat3 and
Stat3-dependent cytokines have been reported to limit iTreg cell
generation during GVHD (Pallandre et al., 2007; Laurence et al.,
2012). Indirect support for this premise also comes from the fact
that the only study in which iTreg cells that were generated by allo-
geneic dendritic cell stimulation were able to mitigate GVHD and
maintain their suppressive phenotype (Sela et al., 2011) was one
which employed a non-irradiation GVHD model where inflam-
matory cytokine production is more attenuated. Apart from block-
ing Stat 3-dependent cytokines as a strategy to augment iTreg cell
reconstitution in vivo, an alternative approach has involved the
culture of CD4+CD25− T cells with the hypomethylating agent 5-
azacytidine. Choi et al. (2010) reported that this treatment induced
Foxp3 expression in conventional CD4+ T cells both in vitro and
in vivo, and that transplantation of these cells ameliorated GVHD
severity.
We would note that instability of Foxp3 expression has also
been noted to occur in nTreg cells in non-transplant models (Zhou
et al., 2009; Pillai et al., 2011) as well as in GVHD (Laurence et al.,
2012), where these cells can revert to a proinflammatory pheno-
type under inflammatory conditions. Thus, inflammation appears
to affect Foxp3 stability in both CD4+ Treg cell populations.
CD8+ TREG CELLS IN GVHD
Foxp3+ Treg cells are classically defined as being a subset of the
CD4+ T cell compartment. However, a CD8+ Foxp3+ Treg popu-
lation has been described and found to be capable of suppressing
T cell responses in animal models of autoimmunity and allergen
exposure (Hahn et al., 2005; Tsai et al., 2010; Wong et al., 2010).
Furthermore, these cells have been shown to play a suppressive role
in patients that have undergone autologous HSCT for systemic
lupus erythematosus, and robust reconstitution of this cell popu-
lation has been associated with more durable remissions (Zhang
et al., 2009). CD8+ Foxp3+ T cells have also been documented in
the tumor microenvironment of patients with colon and prostate
cancer, suggesting that they may be a mechanism by which tumors
escape immune surveillance (Kiniwa et al., 2007; Chaput et al.,
2009). With respect to GVHD, work by three independent groups
reported that a suppressive population of CD8+ Foxp3+ iTreg
cells are induced early during GVHD (Beres et al., 2012; Robb
et al., 2012; Sawamukai et al., 2012). Like their CD4+ counter-
parts, these cells were found to be dependent on TGF-β and IL-2
for induction (Sawamukai et al., 2012) and comprised up to 70%
of the total iTreg population post transplantation (Beres et al.,
2012). Using different methodologic approaches, all three studies
also demonstrated that at least one functionally competent CD4+
or CD8+ iTreg cell population was required to prevent increased
GVHD-associated mortality (Beres et al., 2012; Robb et al., 2012;
Sawamukai et al., 2012). Interestingly, a small adoptively trans-
ferred population of CD8+ iTreg cells could be expanded in GVHD
recipients using IL-2 antibody complexes in conjunction with
Rapamycin as has been previously described with CD4+ Treg cells
(Shin et al., 2011; Robb et al., 2012). Recently, alloantigen-specific
human CD8+ Foxp3+ T cells have been induced in vitro and found
to suppress GVHD in a humanized mouse model (Zheng et al.,
2012). Protection was associated with a reduction in chemokine
and inflammatory cytokine production. These data suggest that
these cells may also be relevant in human allogeneic HSCT for the
protection from lethal GVHD. Since these cells do not exist in the
naïve state, however, they will likely need to be expanded using
in vitro or in vivo methodological approaches for translational
application.
ROLE OF TREG CELLS IN HUMAN GVHD
The approach that has been employed to address whether Treg cells
may serve to modulate the severity of GVHD in man has been to
correlate the absolute number and/or frequency of Tregs with the
subsequent incidence and severity of aGVHD and cGVHD. Sev-
eral reports have demonstrated a decreased frequency of Treg cells
in the peripheral blood of patients with high clinical grades of
aGVHD as compared to patients with lower grade aGVHD or no
GVHD (Li et al., 2010; Bremm et al., 2011). Moreover, Treg cell
frequency was shown to be reduced by as much as 40% in the
peripheral blood of allogeneic HSCT recipients that developed
GVHD as compared to autologous or allogeneic HSCT recipients
that displayed no signs of GVHD (Magenau et al., 2010). Similar
results have also been observed in cGVHD, where the frequency of
Treg cells negatively correlated with disease severity (Zorn et al.,
2005; Li et al., 2010; McIver et al., 2012). Whereas most human
studies have examined peripheral blood Treg cells; Rieger et al.
assessed mucosal Treg cell frequencies in intestinal biopsies, which
are perhaps a more relevant marker of disease. This group reported
that the ratio of Foxp3+ Treg cells to CD8+ T cells was significantly
decreased at the mucosal interface of GVHD patients as com-
pared to patients with intestinal inflammation unrelated to GVHD
(Rieger et al., 2006). Although most of these human studies have
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examined Treg cell frequency several weeks post transplantation
after the establishment of GVHD, one report found that the ratio
of Treg cells to T cells was decreased in aGVHD patients within
2 weeks of transplantation, prior to disease onset, suggesting that
this ratio may also be a good clinical predictor of GVHD (Fujioka
et al., 2013).
It is important to note, however, that not all studies have
demonstrated a correlation between reduced Treg frequency and
GVHD severity. Clark et al. (2004) observed that cGVHD patients
had increased numbers of peripheral blood CD4+CD25hi Treg
cells as compared to individuals without GVHD. This was sup-
ported by a more recent study that reported increased peripheral
Treg cell numbers in transplant recipients that developed cGVHD
with no prior aGVHD diagnosis (Ukena et al., 2011a). Interest-
ingly, the same study found decreased peripheral blood Treg cell
frequencies in patients whose aGVHD transitioned into cGVHD,
although the frequency of Treg cells in these patients increased
over a 6-month observation period (Ukena et al., 2011a). Treg
cells isolated from the peripheral blood of GVHD patients were
also found to display normal suppressive function (Clark et al.,
2004; Noel et al., 2008). Arimoto et al. (2007) employed an alterna-
tive strategy and demonstrated no significant correlation between
Foxp3 expression and the incidence of either aGVHD or cGVHD,
as measured by mRNA isolated from peripheral blood lympho-
cytes from allogeneic HSCT recipients. Finally, gastric biopsies
had comparable mucosal Treg cell frequencies in patients with
gastric GVHD and patients with no GVHD, suggesting that Treg
cell frequencies do not correspond to disease incidence or severity
in this tissue site (Lord et al., 2011).
The reason for the differences observed in these studies is not
entirely clear. For the most part, however, studies that have failed
to demonstrate that a reduction in Treg cell frequency and/or
absolute numbers is associated with increased GVHD severity
have relied on CD25 expression to delineate Treg cell popula-
tions, whereas those that have reported a positive correlation have
tended to employ Foxp3 expression as a readout for this Treg cell
population. Thus, it is possible that the reliance on different phe-
notypic markers may result in somewhat different populations
being examined and be a potential explanation for these discordant
results.
DONOR-DERIVED TREG CELLS IN HUMAN HSCT
An alternative approach to examine the effect of Treg cells on
GVHD severity in human allogeneic HSCT has been to assess the
number of donor-derived Treg cells within the graft prior to trans-
plantation. In this regard, Rezvani et al. (2006) determined that
increased frequencies of CD4+Foxp3+ Treg cells in the periph-
eral blood of the donor negatively correlated with the incidence of
GVHD in the graft recipient. Several subsequent studies confirmed
this correlation in recipients of HLA-identical sibling and unre-
lated donor stem cell grafts (Pabst et al., 2007; Wolf et al., 2007),
indicating that hematopoietic stem cell graft content appears to
modulate GVHD severity. Notably, Blache and colleagues reported
that although peripheral blood stem cell (PBSC) grafts include
increased numbers of CD4+CD25+CD127lo Treg cells as com-
pared to bone marrow grafts, the frequency of peripheral blood
Treg cells is reversed post transplantation. This was presumed to be
due to the fact that PBSC Treg cells tended to be CD62Llo as a con-
sequence of both granulocyte colony stimulating factor treatment
for mobilization and the subsequent leukapheresis process (Blache
et al., 2010). In that regard, increased numbers of CD62L+ Treg
cells in the graft have been found to correlate with reduced GVHD
incidence (Lu et al., 2011), which is likely due to the ability of these
cells to enter the secondary lymphoid tissue where allorecognition
by donor T cells and GVHD initiation occurs. This is consistent
with what has been reported in rodent models of GVHD where
the CD62L+ Treg cell population is more potent at suppressing
GVHD than the corresponding CD62Llo population (Taylor et al.,
2004).
TREG CELL CLINICAL TRIALS
Less than two decades after their discovery, Treg cells are now enter-
ing into clinical trials in allogeneic HSCT recipients. Pre-clinical
murine models of GVHD have provided much insight into Treg
cell-based therapy, but most mouse studies have been performed
using Foxp3-GFP reporter mice where Foxp3-expressing Treg cells
can be definitively isolated for adoptive transfer studies. This is not
a luxury that is available in human studies where CD25 expression
necessarily serves as a surrogate for Foxp3. However, since CD25
is upregulated on all activated T cells, further phenotypic charac-
terization of these cells has been generally thought to be necessary
for their use in man. To that end, Ukena et al. (2011b) compared
the phenotype, function, and stability of many Treg cell subsets
and deemed that CD4+CD25hiCD127− or CD4+CD25hiICOS+
Treg populations were likely to be most suitable for human adop-
tive transfer studies. Many groups have also identified in vitro
expansion protocols that yield high number of Treg cells for adop-
tive transfer (Karakhanova et al., 2006; Hippen et al., 2011a,b;
Veerapathran et al., 2011; Chakraborty et al., 2013; Golab et al.,
2013). Recently, Hippen et al. (2011a) utilized rapamycin and
TGF-β treatment to generate and expand iTreg cells, which were
potent suppressors in a xenogeneic model of GVHD. Likewise,
Chakraborty et al. defined a protocol for the large-scale expan-
sion of nTreg cells. These ex vivo-expanded cells also amelio-
rated disease in a xenograft model of GVHD (Chakraborty et al.,
2013).
One of the first reported clinical studies was conducted by
Brunstein et al. who performed a phase I clinical prophylaxis trial
with cord blood-derived Treg cells. The rationale for the use of
cord blood-derived Treg cells was based, in part, on earlier stud-
ies, that had shown that they express similar levels of CTLA-4,
Foxp3, GITR, and CD25 as adult peripheral blood Treg cells, and
when stimulated by alloantigen, were potent suppressors of T cell
expansion (Chang et al., 2005). Furthermore, cord blood Treg cells
were shown to be resistant to immunosuppressant drugs that are
commonly used to treat GVHD (Porter et al., 2006) and could
therefore interfere with Treg suppressive function. In this phase I
trial, Brunstein et al. (2011) demonstrated that these cells could
be safely administered, but whether they had a role in protecting
patients from GVHD could not be adequately assessed due to the
design of the study.
A second clinical trial was performed by Di Ianni et al. (2011),
in which Treg cells were adoptively transferred into patients receiv-
ing haploidentical transplants. This was also a prophylaxis trial but
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the source of Treg cells was from the donors who also provided
the stem cells that were used to engraft the patients, as opposed
to cord blood. In this report,>90% of enrolled patients engrafted
and only 2/26 patients had ≥grade 2 aGVHD. No patient had
developed cGVHD at the time of publication.
There has been one small study involving two patients in which
expanded Treg cells were administered to patients with docu-
mented GVHD (Trzonkowski et al., 2009), as opposed to being
given to prevent disease. Cells were obtained from family donors
who were HLA-identical with the recipients, activated with anti-
CD3/CD28 beads and then cultured in high doses of IL-2 for
3 weeks. One patient had cGVHD, while the second had refractory
aGVHD. The former patient had a partial response as determined
by the ability to reduce concurrent immune suppressive agents
along with objective improvement in some clinical parameters.
The latter patient, however, had no sustained improvement despite
multiple Treg cell infusions.
An alternative approach to harness the potential for Treg cell
therapy in humans is based on the requirement of these cells for
IL-2. Specifically, Zorn et al. (2009) found that IL-2 therapy in
combination with CD4+ donor leukocyte infusions, used to treat
relapsed hematologic malignancies post HSCT, resulted in Treg
cell expansion in vivo. This same group then utilized this strategy
to treat glucocorticoid refractory cGVHD patients. The adminis-
tration of low dose IL-2 was associated with an amelioration of
disease severity and this correlated with an increase in the num-
ber of Treg cells (Koreth et al., 2011). Thus, the administration of
cytokines capable of inducing the in vivo expansion of Treg cells
may be a more clinically feasible strategy to enhance Treg reconsti-
tution post transplantation, as compared to more costly expansion
strategies.
Collectively, these studies are exciting evidence that Treg
cell therapy has now entered into the clinic. Going forward,
well-designed trials will be necessary to determine whether these
cells are indeed capable of preventing and/or treating patients with
established GVHD.
UNRESOLVED QUESTIONS
Despite the significant progress that has been made in under-
standing the role of Treg cells in GVHD biology, a number of
questions remain. First of all, the relative roles of CD4+ nTreg cells,
CD4+ iTreg cells, and CD8+ iTreg cells in GVHD biology remain
unclear. Elucidating the mechanisms by which the respective cell
subsets function may provide insight for developing better thera-
peutic strategies. Furthermore, additional studies are required to
ascertain whether CD4+ and CD8+ Treg cell populations function
cooperatively or whether they have overlapping redundant roles
in GVHD biology.
Secondly, accumulating evidence indicates that Treg popula-
tions, particularly those that are expanded in vitro, have unstable
Foxp3 expression. Since Foxp3 expression is necessary for sup-
pressive function, further inquiry is needed to determine whether
Foxp3 expression can be stabilized especially under pro inflamma-
tory conditions which characterizes the GVHD milieu (Koenecke
et al., 2009; Beres et al., 2012; Laurence et al., 2012).
Finally, current Treg cell-based immunotherapy approaches
rely on the expansion of polyclonal populations of Treg cells. The
best source of Treg cells and the optimal culture conditions for
ex vivo expansion remain unresolved. Moreover, it is possible that
alloantigen-specific Treg cells may be more potent in suppressing
GVHD, and should be studied further (Albert et al., 2005; Gaidot
et al., 2011; Sagoo et al., 2012). A potential advantage of this strat-
egy is that adoptively transferred Treg cells may not suppress the
immune response to third party antigens which could preserve
the ability of patients to mount competent anti-infectious and
anti-tumor immunity (Gaidot et al., 2011).
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